Trinity College Dublin

Skip to main content.

Top Level TCD Links

Featured Research

Dr. Carlos Medina MD

Dr. Carlos Medina MD, PhD is a specialist gastroeneterologist with very strong interests in colonic inflammation and cancer. His research is under the IBD, platelets and pharmaceutical nanoscience group interests.

Inflammatory bowel disease (IBD) is a chronic relapsing condition with inflammation and tissue remodelling of the gastrointestinal tract whose aetiology is still unknown. I t has been suggested that IBD may result from a dysregulated response of the intestinal immune system towards intraluminal antigens of bacterial origin leading to the activation and release of several factors resulting in intestinal injury. In addition, currently there is no ultimate cure for IBD patients. Existing therapies may alleviate inflammatory symptoms; however, IBD patients are likely to suffer many relapses over the course of the disease. According to the Economic and Social Research Institute (ESRI), approximately 3000 patients suffering from IBD are admitted to different Irish Hospitals every year for the treatment of this condition or its complications.

Colorectal cancer is one of the most frequent cancers in our society and patients may die due to metastasis. Colon cancer progression to the metastasic phenotype is mainly dependent on tumour cell invasiveness. Platelets may play an important role in metastasis development but the underlying molecular mechanisms implicated remain poorly understood. The use of pharmacological agents is frequently limited by low efficacy or lack of selectivity. In addition, many drugs can be quickly cleared in the body by the reticuloendothelial system. Furthermore, the efficacy of different cytotoxic drugs is often limited by several side effects. Thus, a carrier system that delivers the drug specifically and exclusively to the affected region for a prolonged period of time would be desirable and could reduce side effects significantly.

Summary of cells & mediators

Research interests:

My research interests are focused on 3 out of 4 School’s strategic research strands, such as inflammatory bowel disease, thrombosis and cancer, and nanomedicine.

  • My primary research objective is the identification and characterization of different molecular targets involved in IBD and cancer. Preliminary results indicate that matrix metalloproteinase-9 (mmp-9), different isoforms of protein kinase c (PKC) and mitogen- activated protein kinase (MAPk) may be among targets to be considered
  • The secondary research objective is to design new effective therapeutic strategies for IBD and colon cancer, including selective MMP-9 inhibitors. In collaboration with Departamento de Química Orgánica y Bio-Orgánica, Facultad de Ciencias, UNED, Madrid, we have found that new curcuminoid pyrazoles are able to down-regulate MMP-9 activity on inflammation-induced intestinal epithelial cells.

And finally, my work will be also focused on novel nanoparticle-based therapeutics of IBD and colonic cancer.

Expression of MMP-9

National Collaborations:

  • Prof MW Radomski, Schhol of Pharmacy, TCD
  • Prof Colm O’Morain, Tallaght Hospital
  • Prof Padriac Fallon, Institute of Molecular Medicine, TCD
  • Dr J Gilmer, Schhol of Pharmacy, TCD
  • Dr A Harkin, Schhol of Pharmacy, TCD
  • Dr C Ehrhardt, Schhol of Pharmacy, TCD
  • Dr N Frankish, Schhol of Pharmacy, TCD
  • Dr H Sheridan, Schhol of Pharmacy, TCD

International Collaborations:

  • Dr RM Claramunt, Departamento de Química Orgánica y Bio-Orgánica, Facultad de Ciencias, UNED, Madrid, Spain
  • Dr F Guarner, Hospital Vall d’Hebron, Autonomous University of Barcelona, Spain
  • Prof I. Lizasoain, Departamento de Farmacología, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain.
  • Dr A Santana, Research Unit, Hospital de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain

Funding Agencies:

  • Enterprise Ireland

Recent publications (last 5 years):

  2. 2) MJ Santos-Martinez, C Medina, P Jurasz, MW Radomski. THE ROLE OF METALLOPROTEINASES IN PLATELET FUNCTION. Thromb Res 2008;121:535-42.
  3. S Videla, A Lugea, J Vilaseca, F Guarner, F Treserra, A Salas, E Crespo, C Medina, JR Malagelada. POLYETHYLENE GLYCOL ENHANCES COLONIC BARRIER FUNCTION AND AMELIORATES EXPERIMENTAL COLITIS IN RATS. Int J Colorectal Dis 2007;22:571-580.
  4. C Medina, MJ Santos-Martinez, A. Radomski, I Owen, MW Radomski. NANOPARTICLES: PHARMACOLOGICAL AND TOXICOLOGICAL SIGNIFICANCE. Br J Pharmacol 2007;150:552-8
  5. S Videla, J Vilaseca, C Medina, M Mourelle, F Guarner, A Salas, J-R Malagelada. MODULATORY EFFECT OF NITRIC OXIDE ON MAST CELLS IN DEXTRAN SULPHATE SODIUM-INDUCED COLITIS. Dig Dis Sci 2007, 52:45-51
  6. AZ Gimeno-García, A Santana, A Jiménez, A Parra-Blanco, D Nicolás-Pérez, C Paz-Cabrera, F Díaz-González, C Medina, L Díaz-Flores, E Quintero. Up-regulation of gelatinases in the colorectal adenoma-carcinoma sequence. Eur J Cancer 2006;42:3246-52
  7. A Parra-Blanco, AZ Gimeno-García, D Nicolás- Pérez, C García, C Medina, L Díaz-Flores, B Grosso, A Jiménez, E Quintero. RISK FOR HIGH-GRADE DYSPLASIA OR INVASIVE CARCINOMA IN COLORECTAL FLAT ADENOMAS. Gastroenterol Hepatol 2006;29:602-9
  8. A Santana, C Medina, MC Paz, F Díaz, E Farre, A Salas, MW Radomski, E Quintero. ATTENUATION OF DEXTRAN SODIUM SULPHATE-INDUCED COLITIS IN MATRIX METALLOPROTEINASE-9 DEFICIENT MICE. World J Gastroenterol 2006;12:6464-72
  9. C Medina, A Santana, MC Paz-Cabrera, A Parra-Blanco, D Nicolas-Perez, Z Gimeno-Garcia, E Quintero. INCREASED ACTIVITY AND EXPRESSION OF GELATINASES IN ISCHEMIC COLITIS. Dig Dis Sci 2006;51:2393-9
  10. C Medina, Radomski MW. ROLE OF MATRIX METALLOPROTEINASAS IN INTESTINAL INFLAMMATION. J Pharmacol Exp Ther, 2006;318:933-8.
  11. D Alonso-Escolano, C Medina, K Cieslik, A Radomski, P Jurasz, MJ Santos-Martinez, P Ruvolo, MW Radomski. PKCδ MEDIATES PLATELET-INDUCED BREAST CANCER CELL INVASION. J Pharmacol Exp Ther, 2006;318:373-80.
  12. C Medina, A Santana, MC Paz, F Díaz, E Farre, A Salas, MW Radomski, E Quintero. MATRIX METALLOPROTEINASE-9 MODULATES INTESTINAL INJURY IN RATS WITH TRANSMURAL COLITIS. J Leukoc Biol 2006;79:954-62.
  13. C Medina, P Jurasz, MJ Santos-Martinez, SS Jeong, T Mitsky, R Chen, MW Radomski. PLATELET AGGREGATION-INDUCED BY CACO-2 CELLS: REGULATION BY MATRIX METALLOPROTEINASE-2 AND ADENOSINE DIPHOSPHATE. J Pharmacol Exp Ther 2006;317:739-45.
  14. S Videla, J Vilaseca, C Medina, M Mourelle, F Guarner, A Salas, J-R Malagelada. PHOSPHODIESTERASE-IV INHIBITION PREVENTS CHRONIC COLITIS AND INTESTINAL FIBROSIS. J Pharmacol Exp Ther 2006;316:940-945.
  15. F Casellas, JI Arenas, S Baudet, S Fábregas, N García, J Gelabert, C Medina, I Ochotorena, M Papo, L Rodrigo, J-R Malagelada. IMPAIREMENT OF HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. A SPANISH MULTICENTER STUDY. Inflamm Bowel Dis 2005;11:488-496.
  16. C Medina, A Santana, M LLopis, MC Paz-Cabrera, M Antolin, F Guarner, J Vilaseca, M Mourelle, C Gonzalez, A Salas, E Quintero, JR Malagelada. TRANSMURAL COLONIC INFLAMMATION INDUCED BY BACTEROIDES FRAGILIS: IMPLICATION OF MATRIX METALLOPROTEINASES. Inflamm Bowel Dis 2005; 11: 99-105.
  17. AZ Gimeno, A Parra-Blanco, J Ortega, D Nicolás, C Medina, E Quintero. COLONIC DIEULAFOY LESIONS TREATED ENDOSCOPICALLY WITH HEMOCLIPS. Dis Colon Rectum. 2004; 47(9):1539-43.
  18. C Medina, J Vilaseca, S Videla, R Fabra, JR Armengol-Miró, JR Malagelada. OUTCOME OF PATIENTS WITH ISCHEMIC COLITIS: REVIEW OF FIFTY THREE CASES. Dis Colon Rectum 2004; 47(2):180-4. is. 2005 Feb;11(2):99-105.

Back to top

Last updated 9 September 2016 by School of Pharmacy & Pharmaceutical Sciences (Email).